Oric Pharmaceuticals (ORIC) Stock Price, News & Analysis

Company Overview

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers. It has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Key Stats

• Today's Range: $9.67 to $10.05
• 50-Day Range: $9.03 to $11.80
• 52-Week Range: $3.90 to $14.67
• Volume: 870,992 shs
• Average Volume: 1.30 million shs
• Market Capitalization: $961.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $17.63
• Consensus Rating: Moderate Buy

Oric Pharmaceuticals Stock Analysis - MarketRank™

Oric Pharmaceuticals scored higher than 94% of companies evaluated by MarketBeat, and ranked 149th out of 1,876 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Oric Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Oric Pharmaceuticals has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Oric Pharmaceuticals are expected to grow in the coming year, from ($2.17) to ($1.96) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Oric Pharmaceuticals is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oric Pharmaceuticals is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Oric Pharmaceuticals has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

8.51% of the float of Oric Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Oric Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Oric Pharmaceuticals has recently decreased by 45.00%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Oric Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Oric Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.16

Percentage of Shares Shorted

8.51% of the float of Oric Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Oric Pharmaceuticals has a short interest ratio ("days to cover") of 5.1.

Change versus previous month

Short interest in Oric Pharmaceuticals has recently decreased by 45.00%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.04

News Sentiment

Oric Pharmaceuticals has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for Oric Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

Only 3 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of -40% compared to the previous 30 days.

MarketBeat Follows

10 people have added Oric Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oric Pharmaceuticals insiders have sold 58.30% more of their company's stock than they have bought. Specifically, they have bought $262,976.00 in company stock and sold $416,289.00 in company stock.

Percentage Held by Insiders

Only 5.55% of the stock of Oric Pharmaceuticals is held by insiders.

Percentage Held by Institutions

95.05% of the stock of Oric Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ORIC Stock Analysis - Frequently Asked Questions

How have ORIC shares performed this year?

Oric Pharmaceuticals' stock was trading at $8.07 at the start of the year. Since then, ORIC shares have increased by 22.7% and is now trading at $9.90.

How were Oric Pharmaceuticals' earnings last quarter?

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) released its quarterly earnings results on Tuesday, August, 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by $0.01.

When did Oric Pharmaceuticals IPO?

Oric Pharmaceuticals (ORIC) raised $75 million in an initial public offering on Friday, April 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities served as the underwriters for the IPO.

Who are Oric Pharmaceuticals' major shareholders?

Oric Pharmaceuticals' top institutional investors include Alkeon Capital Management LLC (4.64%), Vivo Capital LLC (3.67%), Balyasny Asset Management L.P. (1.83%) and MPM Bioimpact LLC (1.78%). Insiders that own company stock include Jacob Chacko, Dominic Piscitelli, Pratik S Multani and Angie You.
View institutional ownership trends.

How do I buy shares of Oric Pharmaceuticals?

Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Oric Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Oric Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 8/18/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ORIC
• CIK: 1796280
• Web: www.oricpharma.com
• Phone: 650-388-5600
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Oric Pharmaceuticals: $17.63
• High Price Target: $20.00
• Low Price Target: $12.00
• Potential Upside/Downside: +78.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$127.85 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -51.75%
• Return on Assets: -47.09%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 16.13
• Quick Ratio: 16.13

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.45 per share
• Price / Book: 2.87

Miscellaneous

• Outstanding Shares: 97,120,000
• Free Float: 91,733,000
• Market Cap: $961.00 million
• Optionable: Optionable
• Beta: 1.69